The long-term outcomes of operated and nonoperated patients with chronic thromboembolic pulmonary hypertension were reported in a large, prospective, multicentre, European and Canadian registry. The long-term prognosis of operated patients was superior to that of nonoperated patients, indicating that surgery should be the first-choice treatment in this patient cohort.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Madani, M. M. et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann. Thorac. Surg. 94, 97–103 (2012).
Delcroix, M. et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016522, (2016).
Galiè, N. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 46, 903–975 (2015).
Kim, N. H. et al. Chronic thromboembolic pulmonary hypertension. J. Am. Coll. Cardiol. 62 (Suppl.), D92–D99 (2013).
Riedel, M., Stanek, V., Widimsky, J. & Prerovsky, I. Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest 81, 151–158 (1982).
Saouti, N. et al. Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respir. Med. 103, 1013–1019 (2009).
Ghofrani, H. A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369, 319–329 (2013).
Simonneau, G. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur. Respir. J. 45, 1293–1302 (2015).
Mizoguchi, H. et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ. Cardiovasc. Interv. 5, 748–755 (2012).
Roik, M. et al. Refined balloon pulmonary angioplasty driven by combined assessment of intra-arterial anatomy and physiology — multimodal approach to treated lesions in patients with non-operable distal chronic thromboembolic pulmonary hypertension — technique, safety and efficacy of 50 consecutive angioplasties. Int. J. Cardiol. 203, 228–235 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.V.N. declares that he receives lecture fees from Actelion, Bayer, Eli Lilly, GlaxoSmithKline, and Pfizer; is on the industry advisory board for Actelion and Bayer; and is serving on steering committees for Actelion, Bayer, and Pfizer. H.J.B. declares that he receives lecture fees from GlaxoSmithKline and Pfizer.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Noordegraaf, A., Bogaard, H. Surgery remains treatment of choice for CTEPH. Nat Rev Cardiol 13, 188–189 (2016). https://doi.org/10.1038/nrcardio.2016.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.30
